Empagliflozin in women with type 2 diabetes and cardiovascular disease – an analysis of EMPA-REG OUTCOME®

Effects of empagliflozin on risk for cardiovascular death and heart failure hospitalization across the spectrum of heart failure risk in the EMPA-REG OUTCOME® trial

(2017) David Fitchett et al.   EUROPEAN HEART JOURNAL

Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME®trial

(2016) David Fitchett et al.   EUROPEAN HEART JOURNAL

Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes

(2016) Christoph Wanner et al.   NEW ENGLAND JOURNAL OF MEDICINE

Efficacy and safety of empagliflozin in type 2 diabetes mellitus: a meta-analysis of randomized controlled trials

(2016) R. Devi et al.   POSTGRADUATE MEDICINE

Sex-Specific Differential in Risk of Diabetes-Related Macrovascular Outcomes

(2015) Amanda Lyon et al.   Current Diabetes Reports

Design and baseline characteristics of the CARdiovascular Outcome Trial of LINAgliptin Versus Glimepiride in Type 2 Diabetes (CAROLINA®)

(2015) Nikolaus Marx et al.   Diabetes & Vascular Disease Research

Risk factors, treatment and prognosis in men and women with heart failure with and without diabetes

(2015) Isabelle Johansson et al.   HEART

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes

(2015) Bernard Zinman et al.   NEW ENGLAND JOURNAL OF MEDICINE

Cigarette smoking exposure and heart failure risk in older adults: The Health, Aging, and Body Composition Study

(2012) Deepa M. Gopal et al.   AMERICAN HEART JOURNAL

Status of Women in Cardiovascular Clinical Trials

(2009) Esther S.H. Kim et al.   ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY